Cargando…

Investigation of safety for electrochemotherapy and irreversible electroporation ablation therapies in patients with cardiac pacemakers

BACKGROUND: The effectiveness of electrochemotherapy of tumors (ECT) and of irreversible electroporation ablation (IRE) depends on different mechanisms and delivery protocols. Both therapies exploit the phenomenon of electroporation of the cell membrane achieved by the exposure of the cells to a ser...

Descripción completa

Detalles Bibliográficos
Autores principales: Jarm, Tomaz, Krmac, Tadej, Magjarevic, Ratko, Kos, Bor, Cindric, Helena, Miklavcic, Damijan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667796/
https://www.ncbi.nlm.nih.gov/pubmed/33198769
http://dx.doi.org/10.1186/s12938-020-00827-7
_version_ 1783610384918249472
author Jarm, Tomaz
Krmac, Tadej
Magjarevic, Ratko
Kos, Bor
Cindric, Helena
Miklavcic, Damijan
author_facet Jarm, Tomaz
Krmac, Tadej
Magjarevic, Ratko
Kos, Bor
Cindric, Helena
Miklavcic, Damijan
author_sort Jarm, Tomaz
collection PubMed
description BACKGROUND: The effectiveness of electrochemotherapy of tumors (ECT) and of irreversible electroporation ablation (IRE) depends on different mechanisms and delivery protocols. Both therapies exploit the phenomenon of electroporation of the cell membrane achieved by the exposure of the cells to a series of high-voltage electric pulses. Electroporation can be fine-tuned to be either reversible or irreversible, causing the cells to either survive the exposure (in ECT) or not (in IRE), respectively. For treatment of tissues located close to the heart (e.g., in the liver), the safety of electroporation-based therapies is ensured by synchronizing the electric pulses with the electrocardiogram. However, the use of ECT and IRE remains contraindicated for patients with implanted cardiac pacemakers if the treated tissues are located close to the heart or the pacemaker. In this study, two questions are addressed: can the electroporation pulses interfere with the pacemaker; and, can the metallic housing of the pacemaker modify the distribution of electric field in the tissue sufficiently to affect the effectiveness and safety of the therapy? RESULTS: The electroporation pulses induced significant changes in the pacemaker ventricular pacing pulse only for the electroporation pulses delivered during the pacing pulse itself. No residual effects were observed on the pacing pulses following the electroporation pulses for all tested experimental conditions. The results of numerical modeling indicate that the presence of metal-encased pacemaker in immediate vicinity of the treatment zone should not impair the intended effectiveness of ECT or IRE even when the casing is in direct contact with one of the active electrodes. Nevertheless, the contact between the casing and the active electrode should be avoided due to significant tissue heating at the site of the other active electrode for the IRE protocol and may cause the pulse generator to fail to deliver the pulses due to excessive current draw. CONCLUSIONS: The observed effects of electroporation pulses delivered in close vicinity of the pacemaker or its electrodes do not indicate adverse consequences for either the function of the pacemaker or the treatment outcome. These findings should contribute to making electroporation-based treatments accessible also to patients with implanted cardiac pacemakers.
format Online
Article
Text
id pubmed-7667796
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-76677962020-11-17 Investigation of safety for electrochemotherapy and irreversible electroporation ablation therapies in patients with cardiac pacemakers Jarm, Tomaz Krmac, Tadej Magjarevic, Ratko Kos, Bor Cindric, Helena Miklavcic, Damijan Biomed Eng Online Research BACKGROUND: The effectiveness of electrochemotherapy of tumors (ECT) and of irreversible electroporation ablation (IRE) depends on different mechanisms and delivery protocols. Both therapies exploit the phenomenon of electroporation of the cell membrane achieved by the exposure of the cells to a series of high-voltage electric pulses. Electroporation can be fine-tuned to be either reversible or irreversible, causing the cells to either survive the exposure (in ECT) or not (in IRE), respectively. For treatment of tissues located close to the heart (e.g., in the liver), the safety of electroporation-based therapies is ensured by synchronizing the electric pulses with the electrocardiogram. However, the use of ECT and IRE remains contraindicated for patients with implanted cardiac pacemakers if the treated tissues are located close to the heart or the pacemaker. In this study, two questions are addressed: can the electroporation pulses interfere with the pacemaker; and, can the metallic housing of the pacemaker modify the distribution of electric field in the tissue sufficiently to affect the effectiveness and safety of the therapy? RESULTS: The electroporation pulses induced significant changes in the pacemaker ventricular pacing pulse only for the electroporation pulses delivered during the pacing pulse itself. No residual effects were observed on the pacing pulses following the electroporation pulses for all tested experimental conditions. The results of numerical modeling indicate that the presence of metal-encased pacemaker in immediate vicinity of the treatment zone should not impair the intended effectiveness of ECT or IRE even when the casing is in direct contact with one of the active electrodes. Nevertheless, the contact between the casing and the active electrode should be avoided due to significant tissue heating at the site of the other active electrode for the IRE protocol and may cause the pulse generator to fail to deliver the pulses due to excessive current draw. CONCLUSIONS: The observed effects of electroporation pulses delivered in close vicinity of the pacemaker or its electrodes do not indicate adverse consequences for either the function of the pacemaker or the treatment outcome. These findings should contribute to making electroporation-based treatments accessible also to patients with implanted cardiac pacemakers. BioMed Central 2020-11-16 /pmc/articles/PMC7667796/ /pubmed/33198769 http://dx.doi.org/10.1186/s12938-020-00827-7 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Jarm, Tomaz
Krmac, Tadej
Magjarevic, Ratko
Kos, Bor
Cindric, Helena
Miklavcic, Damijan
Investigation of safety for electrochemotherapy and irreversible electroporation ablation therapies in patients with cardiac pacemakers
title Investigation of safety for electrochemotherapy and irreversible electroporation ablation therapies in patients with cardiac pacemakers
title_full Investigation of safety for electrochemotherapy and irreversible electroporation ablation therapies in patients with cardiac pacemakers
title_fullStr Investigation of safety for electrochemotherapy and irreversible electroporation ablation therapies in patients with cardiac pacemakers
title_full_unstemmed Investigation of safety for electrochemotherapy and irreversible electroporation ablation therapies in patients with cardiac pacemakers
title_short Investigation of safety for electrochemotherapy and irreversible electroporation ablation therapies in patients with cardiac pacemakers
title_sort investigation of safety for electrochemotherapy and irreversible electroporation ablation therapies in patients with cardiac pacemakers
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667796/
https://www.ncbi.nlm.nih.gov/pubmed/33198769
http://dx.doi.org/10.1186/s12938-020-00827-7
work_keys_str_mv AT jarmtomaz investigationofsafetyforelectrochemotherapyandirreversibleelectroporationablationtherapiesinpatientswithcardiacpacemakers
AT krmactadej investigationofsafetyforelectrochemotherapyandirreversibleelectroporationablationtherapiesinpatientswithcardiacpacemakers
AT magjarevicratko investigationofsafetyforelectrochemotherapyandirreversibleelectroporationablationtherapiesinpatientswithcardiacpacemakers
AT kosbor investigationofsafetyforelectrochemotherapyandirreversibleelectroporationablationtherapiesinpatientswithcardiacpacemakers
AT cindrichelena investigationofsafetyforelectrochemotherapyandirreversibleelectroporationablationtherapiesinpatientswithcardiacpacemakers
AT miklavcicdamijan investigationofsafetyforelectrochemotherapyandirreversibleelectroporationablationtherapiesinpatientswithcardiacpacemakers